# Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme

> **NCT00050986** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 55 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Temozolomide
- **DRUG:** R115777

## Key facts

- **NCT ID:** NCT00050986
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2020-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050986, "Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00050986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*